Silexion Therapeutics Corp Warrant
SLXNW
About: Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
Employees: 14
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
18.47% more ownership
Funds ownership: 23.82% [Q1] → 42.29% (+18.47%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
16% less funds holding
Funds holding: 25 [Q1] → 21 (-4) [Q2]
49% less capital invested
Capital invested by funds: $199K [Q1] → $102K (-$97.2K) [Q2]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Financial journalist opinion
We haven’t received any recent news articles for SLXNW